Protocol Number: 03-C-0216

Title:

A Groupwide Biology and Banking Study for Ewing Sarcoma: Children's Oncology Group

Number:

03-C-0216

Summary:

Ewing sarcoma is a type of cancer usually found in children and young adults. Researchers use tissue samples of Ewing sarcoma tumors to conduct research with the goal of improving the treatments for this disease.

The purpose of this study is to maintain a tissue bank from tumor biopsies donated by patients with Ewing Sarcoma to learn about genetic changes seen in these tumors.

When Ewing sarcoma is suspected, doctors diagnose the disease by taking a sample of a patient's tumor for evaluation. Some of the tissue from this procedure is usually discarded. Study participants will donate the unused tissue from this diagnostic procedure.

Sponsoring Institute:

National Cancer Institute (NCI)

Recruitment Detail

Type: Active Accrual Of New Subjects

Gender: Male & Female

Referral Letter Required: No

Population Exclusion(s): None

Eligibility Criteria:

INCLUSION CRITERIA:

All newly-diagnosed Ewing sarcoma patients are eligible for this study.

Minimum specimen requirements to enroll a patient on AEWS02B1:

a) Parafin-embedded block or, alternatively, at least 10 (20 are preferred) unstained slides and 1-3 thick (50 micron) sections(s) from the initial biopsy.

b) Pretreatment blood consisting of at least 5 mL (14 mL preferred) of serum and at least 5 mL (10 mL preferred) of whole blood in EDTA (purple top tube).

Additional blood and bone specimens will be required from patients enrolled on a Ewing sarcoma therapeutic trial .

Signed informed consent for AEWS02B1 according to institutional guidelines is required.

Special Instructions: Currently Not Provided

Keywords:

Tissue Banking

Tumor Studies

Recruitment Keywords:

Ewing Sarcoma

Conditions:

Ewing's Sarcoma

Investigational Drug(s):

None

Investigational Device(s):

None

Contacts:

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citations:

Patricio MB, Vilhena M, Neves M, Raposo S, Catita J, De Sousa V, Martins AG. Ewing's sarcoma in children: twenty-five years of experience at the Instituto Portuges de Oncologia de Francisco Gentil (I.P.O.F.G.). J Surg Oncol. 1991 May;47(1):37-40. PMID: 1902537

Kinsella TJ, Miser JS, Waller B, Venzon D, Glatstein E, Weaver-McClure L, Horowitz ME. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):389-95. PMID: 1995522

Gasparini M, Lombardi F, Ballerini E, Gandola L, Gianni MC, Massimino M, Rottoli L, Fossati-Bellani F. Long-term outcome of patients with monostotic Ewing's sarcoma treated with combined modality. Med Pediatr Oncol. 1994;23(5):406-12. PMID: 8084307

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Networks and Applications, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

Warren Grant Magnuson Clinical Center (CC)
National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/15/2004